237 related articles for article (PubMed ID: 23529133)
1. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
[TBL] [Abstract][Full Text] [Related]
2. Target-Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model-Informed Dose Selection for the First-in-Human Study of AVB-S6-500.
Bonifacio L; Dodds M; Prohaska D; Moss A; Giaccia A; Tabibiazar R; McIntyre G
Clin Transl Sci; 2020 Jan; 13(1):204-211. PubMed ID: 31599479
[TBL] [Abstract][Full Text] [Related]
3. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.
Vexler V; Yu L; Pamulapati C; Garrido R; Grimm HP; Sriraman P; Bohini S; Schraeml M; Singh U; Brandt M; Ries S; Ma H; Klumpp K; Ji C
MAbs; 2013; 5(5):776-86. PubMed ID: 23924796
[TBL] [Abstract][Full Text] [Related]
4. Activation of TrkB with TAM-163 results in opposite effects on body weight in rodents and non-human primates.
Perreault M; Feng G; Will S; Gareski T; Kubasiak D; Marquette K; Vugmeyster Y; Unger TJ; Jones J; Qadri A; Hahm S; Sun Y; Rohde CM; Zwijnenberg R; Paulsen J; Gimeno RE
PLoS One; 2013; 8(5):e62616. PubMed ID: 23700410
[TBL] [Abstract][Full Text] [Related]
5. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
[TBL] [Abstract][Full Text] [Related]
6. Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics.
Kwak EY; Kim MJ; Park JH; Jung HW; Jung ME
J Thromb Haemost; 2021 Jun; 19(6):1425-1435. PubMed ID: 33448093
[TBL] [Abstract][Full Text] [Related]
7. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312).
Pawaskar D; Chen X; Glassman F; May F; Roberts A; Biondo M; McKenzie A; Nolte MW; Jusko WJ; Tortorici M
Clin Transl Sci; 2022 Mar; 15(3):709-720. PubMed ID: 34811931
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetic characterization of an adipose tissue-targeting monoclonal antibody in obese and non-obese animals.
Rajan S; Mandikian D; Baruch A; Gelzleichter TR; Stevens D; Sonoda J; Cowan K; Boswell CA; Stefanich E
MAbs; 2017; 9(8):1379-1388. PubMed ID: 28895785
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method.
Song L; Xue J; Zhang J; Li S; Liu D; Zhou T
Eur J Pharm Sci; 2021 Mar; 158():105584. PubMed ID: 33039565
[TBL] [Abstract][Full Text] [Related]
11. First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.
Schaller TH; Snyder DJ; Spasojevic I; Gedeon PC; Sanchez-Perez L; Sampson JH
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273346
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and translational pharmacology of afucosylated anti-CCR8 antibody for depletion of tumour-infiltrating regulatory T cells.
Gampa G; Spinosa P; Getz J; Zhong Y; Halpern W; Esen E; Davies J; Chou C; Kwong M; Wang Y; Arenzana TL; Shivva V; Huseni M; Hsieh R; Schartner J; Koerber JT; Rutz S; Hosseini I
Br J Pharmacol; 2024 Jul; 181(13):2033-2052. PubMed ID: 38486310
[TBL] [Abstract][Full Text] [Related]
13. Population Target-Mediated Pharmacokinetic/Pharmacodynamic Modeling to Evaluate SPI-62 Exposure and Hepatic 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition in Healthy Adults.
Wu N; Katz DA; An G
Clin Pharmacokinet; 2023 Sep; 62(9):1275-1288. PubMed ID: 37452998
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model.
Xin Y; Xiang H; Jin D; Theil FP; Joshi A; Damico-Beyer LA; Bai S
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):217-26. PubMed ID: 22382554
[TBL] [Abstract][Full Text] [Related]
15. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.
Agoram BM
Br J Clin Pharmacol; 2009 Feb; 67(2):153-60. PubMed ID: 19076987
[TBL] [Abstract][Full Text] [Related]
16. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
[TBL] [Abstract][Full Text] [Related]
17. Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy.
Yadav R; Schubbert S; Holder PG; Chiang EY; Kiabi N; Bogaert L; Leung I; Rashid R; Avery KN; Bonzon C; Desjarlais JR; Sanjabi S; Sharma A; Lepherd M; Shelton A; Chan P; Liu Y; Joslyn L; Hosseini I; Stefanich EG; Kamath AV; Bernett MJ; Shivva V
Front Pharmacol; 2024; 15():1380000. PubMed ID: 38887559
[TBL] [Abstract][Full Text] [Related]
18. Model-informed drug development for immuno-oncology agonistic anti-GITR antibody GWN323: Dose selection based on MABEL and biologically active dose.
Ji Y; Knee D; Chen X; Dang A; Mataraza J; Wolf B; Sy SKB
Clin Transl Sci; 2022 Sep; 15(9):2218-2229. PubMed ID: 35731955
[TBL] [Abstract][Full Text] [Related]
19. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods.
Song L; Yao X; Liu Y; Zhong W; Jiang J; Liu H; Zhou H; Shi C; Zong K; Wang C; Ma C; Liu D; Hu P
Eur J Pharm Sci; 2020 Apr; 147():105281. PubMed ID: 32126254
[TBL] [Abstract][Full Text] [Related]
20. Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor.
Chan P; Ding HT; Liederer BM; Mao J; Belloni P; Chen L; Gao SS; Joseph V; Yang X; Lin JS; Mitra MS; Putnam WS; Quartino A; Bauer RN; Pan L
Clin Transl Sci; 2021 Sep; 14(5):1945-1954. PubMed ID: 34058071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
